Intervention Review

Antiangiogenic therapy with anti-vascular endothelial growth factor modalities for neovascular age-related macular degeneration

  1. Satyanarayana S Vedula2,
  2. Magdalena Krzystolik1,*

Editorial Group: Cochrane Eyes and Vision Group

Published Online: 23 APR 2008

Assessed as up-to-date: 19 FEB 2008

DOI: 10.1002/14651858.CD005139.pub2

How to Cite

Vedula SS, Krzystolik M. Antiangiogenic therapy with anti-vascular endothelial growth factor modalities for neovascular age-related macular degeneration. Cochrane Database of Systematic Reviews 2008, Issue 2. Art. No.: CD005139. DOI: 10.1002/14651858.CD005139.pub2.

Author Information

  1. 1

    Southern New England Retina Associates, Providence, USA

  2. 2

    Johns Hopkins Bloomberg School of Public Health, Cochrane Eyes and Vision Group US Project, Baltimore, MD, USA

*Magdalena Krzystolik, Southern New England Retina Associates, 1 Randall Square, Suite 206, Providence, RI 02703, USA. Magdalena_Krzystolik@brown.edu.

Publication History

  1. Publication Status: Edited (no change to conclusions)
  2. Published Online: 23 APR 2008

SEARCH

  1. Current Version

    Antiangiogenic therapy with anti-vascular endothelial growth factor modalities for neovascular age-related macular degeneration

    Satyanarayana S Vedula and Magdalena Krzystolik

    Article first published online: 23 APR 2008 | DOI: 10.1002/14651858.CD005139.pub2

Previous versions of this article and their online publication dates

  1. Version 1

    Antiangiogenic therapy with anti-vascular endothelial growth factor modalities for neovascular age-related macular degeneration

    MG Krzystolik, HA Woodcome and U Reddy

    Article first published online: 24 JAN 2005 | DOI: 10.1002/14651858.CD005139